236 related articles for article (PubMed ID: 32520496)
21. The Clinical Utility of
Nakamoto R; Harrison C; Song H; Guja KE; Hatami N; Nguyen J; Moradi F; Franc BL; Aparici CM; Davidzon G; Iagaru A
Mol Imaging Biol; 2021 Aug; 23(4):614-623. PubMed ID: 33469884
[TBL] [Abstract][Full Text] [Related]
22. Effect of Androgen Deprivation Therapy on the Results of PET/CT with 18F-Fluciclovine in Patients with Metastatic Prostate Cancer.
Bach-Gansmo T; Korsan K; Bogsrud TV
Tomography; 2022 Jun; 8(3):1477-1484. PubMed ID: 35736868
[TBL] [Abstract][Full Text] [Related]
23. Diagnostic performance of 18F-fluciclovine PET/CT for regional lymph node metastases in patients with primary prostate cancer: a multicenter phase II clinical trial.
Suzuki H; Jinnouchi S; Kaji Y; Kishida T; Kinoshita H; Yamaguchi S; Tobe T; Okamura T; Kawakita M; Furukawa J; Otaka A; Kakehi Y
Jpn J Clin Oncol; 2019 Sep; 49(9):803-811. PubMed ID: 31095314
[TBL] [Abstract][Full Text] [Related]
24. New Clinical Indications for (18)F/(11)C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature.
Evangelista L; Briganti A; Fanti S; Joniau S; Reske S; Schiavina R; Stief C; Thalmann GN; Picchio M
Eur Urol; 2016 Jul; 70(1):161-175. PubMed ID: 26850970
[TBL] [Abstract][Full Text] [Related]
25. Initial Institutional Experience with 18F-Fluciclovine PET-CT in Biochemical Recurrence of Prostate Cancer.
Farkas AB; Green ED; Thaggard AL; Vijayakumar V; Henegan JC; Lirette ST; Nittala MR; Vijayakumar S
South Med J; 2021 Nov; 114(11):703-707. PubMed ID: 34729614
[TBL] [Abstract][Full Text] [Related]
26. Differences in Failure-Free Survival After Salvage Radiotherapy Guided by Conventional Imaging Versus
Lawal IO; Jani AB; Adediran OA; Goyal S; Abiodun-Ojo OA; Dhere VR; Marcus CV; Joshi SS; Master VA; Patel PR; Goodman M; Shelton JW; Kucuk O; Hershatter B; Fielder B; Halkar RK; Schuster DM
J Nucl Med; 2023 Apr; 64(4):586-591. PubMed ID: 36328489
[TBL] [Abstract][Full Text] [Related]
27. Impact of
Jani AB; Schreibmann E; Rossi PJ; Shelton J; Godette K; Nieh P; Master VA; Kucuk O; Goodman M; Halkar R; Cooper S; Chen Z; Schuster DM
J Nucl Med; 2017 Mar; 58(3):412-418. PubMed ID: 27609792
[TBL] [Abstract][Full Text] [Related]
28. Diagnostic Performance of 18F-Fluciclovine in Detection of Prostate Cancer Bone Metastases.
Chau A; Gardiner P; Colletti PM; Jadvar H
Clin Nucl Med; 2018 Jul; 43(7):e226-e231. PubMed ID: 29762238
[TBL] [Abstract][Full Text] [Related]
29.
Armstrong JM; Martin CR; Dechet C; Morton K; Evans D; Ambrose J; Maughan BL; O'Neil B; Lowrance W
Urol Oncol; 2020 Jul; 38(7):636.e1-636.e6. PubMed ID: 32317221
[TBL] [Abstract][Full Text] [Related]
30. Superscan 18F-Fluciclovine PET/CT of PSA-Negative Prostate Cancer Bone Metastases.
Chen B; Macapinlac HA; Lu Y
Clin Nucl Med; 2019 Apr; 44(4):337-338. PubMed ID: 30688749
[TBL] [Abstract][Full Text] [Related]
31. Diagnostic accuracy of 18F-fluciclovine PET/CT in primary lymph node staging of prostate cancer.
Hoekstra RJ; Beulens A; Vrijhof EHJEJ; Wyndaele DNJ; Roef M; Brouwer LJM; Somford DM; Sedelaar M; van Basten JA
Nucl Med Commun; 2021 May; 42(5):476-481. PubMed ID: 33323869
[TBL] [Abstract][Full Text] [Related]
32. Does Choline PET/CT Change the Management of Prostate Cancer Patients With Biochemical Failure?
Goldstein J; Even-Sapir E; Ben-Haim S; Saad A; Spieler B; Davidson T; Berger R; Weiss I; Appel S; Lawrence YR; Symon Z
Am J Clin Oncol; 2017 Jun; 40(3):256-259. PubMed ID: 25319322
[TBL] [Abstract][Full Text] [Related]
33. Multisite Experience of the Safety, Detection Rate and Diagnostic Performance of Fluciclovine (
Bach-Gansmo T; Nanni C; Nieh PT; Zanoni L; Bogsrud TV; Sletten H; Korsan KA; Kieboom J; Tade FI; Odewole O; Chau A; Ward P; Goodman MM; Fanti S; Schuster DM; Willoch F
J Urol; 2017 Mar; 197(3 Pt 1):676-683. PubMed ID: 27746282
[TBL] [Abstract][Full Text] [Related]
34. Prostate-specific membrane antigen-positron emission tomography/computed tomography (PSMA-PET/CT)-guided stereotactic ablative body radiotherapy for oligometastatic prostate cancer: a single-institution experience and review of the published literature.
Ong WL; Koh TL; Lim Joon D; Chao M; Farrugia B; Lau E; Khoo V; Lawrentschuk N; Bolton D; Foroudi F
BJU Int; 2019 Nov; 124 Suppl 1():19-30. PubMed ID: 31507035
[TBL] [Abstract][Full Text] [Related]
35. Patterns of Recurrence, Detection Rates, and Impact of 18-F Fluciclovine PET/CT on the Management of Men With Recurrent Prostate Cancer.
Michael J; Khandani AH; Basak R; Tan HJ; Royce TJ; Wallen E; Whang Y; Rose TL; Milowsky M; Bjurlin MA
Urology; 2021 Sep; 155():192-198. PubMed ID: 33516829
[TBL] [Abstract][Full Text] [Related]
36. Utility of
Wang Y; Chow DZ; Ebert E; Tajmir S; Scott JA; Palmer EL
AJR Am J Roentgenol; 2020 Oct; 215(4):997-1001. PubMed ID: 32569513
[No Abstract] [Full Text] [Related]
37. Diagnostic performance of F-18 fluciclovine PET/CT in post-radical prostatectomy prostate cancer patients with rising prostate-specific antigen level ≤0.5 ng/mL.
Teyateeti A; Khan B; Teyateeti A; Chen B; Bridhikitti J; Pan T; Peng W; Macapinlac HA; Lu Y
Nucl Med Commun; 2020 Sep; 41(9):906-915. PubMed ID: 32796479
[TBL] [Abstract][Full Text] [Related]
38. [
Ferrari C; Mammucci P; Lavelli V; Pisani AR; Nappi AG; Rubini D; Sardaro A; Rubini G
Tomography; 2022 Nov; 8(6):2709-2722. PubMed ID: 36412685
[TBL] [Abstract][Full Text] [Related]
39.
Solanki AA; Savir-Baruch B; Liauw SL; Michalski J; Tward JD; Vapiwala N; Teoh EJ;
Pract Radiat Oncol; 2020; 10(5):354-362. PubMed ID: 32464368
[TBL] [Abstract][Full Text] [Related]
40. Reader Training for the Restaging of Biochemically Recurrent Prostate Cancer Using
Miller MP; Kostakoglu L; Pryma D; Yu JQ; Chau A; Perlman E; Clarke B; Rosen D; Ward P
J Nucl Med; 2017 Oct; 58(10):1596-1602. PubMed ID: 28385791
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]